About Amicus Therapeutics
Amicus Therapeutics (NASDAQ:FOLD) is a biotechnology firm focused on discovering, developing, and delivering novel treatments for people living with rare metabolic diseases. With a strong commitment to innovation, Amicus Therapeutics has built a diverse pipeline of therapies aimed at addressing unmet medical needs in conditions that are often overlooked by larger pharmaceutical companies. Among its key projects is the development of enzyme replacement therapies designed to treat genetic disorders at their source. The company's main objective is to provide transformative therapies that improve the quality of life for patients and their families. Through a combination of strategic collaborations and proprietary technologies, Amicus Therapeutics strives to push the boundaries of science and medicine to bring forward potentially life-changing medicines.
Snapshot
Operations
Products and/or services of Amicus Therapeutics
- Galafold (Migalastat) is an oral medication approved for the treatment of adults with a confirmed diagnosis of Fabry disease and who have an amenable genetic mutation.
- AT-GAA (cipaglucosidase alfa and miglustat) is an investigational, two-component therapy designed for the treatment of Pompe disease, aiming to improve muscle function and reduce disease substrate.
- Batten Disease Program focuses on developing therapies for CLN6, CLN3, and CLN8 Batten diseases, rare and fatal genetic disorders that primarily affect the nervous system.
- Fabry Disease Gene Therapy is an investigational gene therapy in preclinical development aimed at providing a functional copy of the GLA gene to Fabry disease patients.
- Pompe Disease Gene Therapy program is developing a next-generation gene therapy for Pompe disease, designed to deliver a functional copy of the GAA gene directly to the patient's cells.
- CDKL5 Deficiency Disorder (CDD) Gene Therapy Program aims to develop a gene therapy treatment for CDD, a rare genetic disorder characterized by early-onset, difficult-to-control seizures and severe neurodevelopmental impairment.
Amicus Therapeutics executive team
- Mr. Bradley L. Campbell M.B.A.CEO, President & Director
- Mr. Simon Nicolas Reade HarfordChief Financial Officer
- Ms. Ellen S. Rosenberg J.D.Chief Legal Officer & Corporate Secretary
- Mr. David M. ClarkChief People Officer
- Dr. Jeffrey P. Castelli Ph.D.Chief Development Officer
- Ms. Samantha L. ProutChief Accounting Officer & Controller
- Dr. Jill Weimer Ph.D.Chief Science Officer
- Mr. Andrew FaughnanVice President of Investor Relations
- Mr. Patrik S. Florencio Esq.Global Chief Compliance & Risk Officer
- Mr. Brendan McEvoyExecutive Director of External Communications